81 results about "DPP-4 Inhibitors" patented technology

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

The present invention relates to methods for treating and / or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

The present invention relates to methods for treating and / or preventing SIRS and / or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of SIRS and / or sepsis.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and / or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and / or a non-oral antidiabetic drug.

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

The invention relates to the related fields of immunology, pharmacy and medicine, discloses a method for preparing a hybridoma cell line and a monoclonal antibody based on B cell epitopes of dipeptidyl peptidase 4 (DPP-4) and an application thereof, and especially, relates to small molecular antigen peptides prepared by coupling the B epitopes of DPP-4 with intramolecular carrier peptides and quickly obtained by a synthetic method; the small molecular antigen peptides immunize mice to produce strong immune response, and can be used for preparing immune spleen lymphocytes and preparing hybrid tumor cells, antibodies and the like. The monoclonal antibody is secreted by the hybridoma cell line (having the preservation number of CCTCC No:C2017227), is a Th2 antibody, is IgG1 in the mice, inhibits the enzyme activity of DPP-4, is specifically combined with DPP-4, can develop a DPP-4 detection reagent and a DPP-4 inhibitor, can significantly reduce blood sugar, uric acid and four indexes ofcreatinine blood lipid, increases GLP-1, regulates oxidative stress and immune balance from Th1 trending to Th2, and reduces pancreatic inflammation; prepared drugs are used for preventing and treating diabetes and complications thereof, hyperuricemia, gout, kidney and liver diseases, hyperlipidemia, AS, cardiovascular diseases and Th1-related diseases.